The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results.
 
Yelena Y. Janjigian
Stock and Other Ownership Interests - Inspirna
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Master Clinician Alliance; Merck; Michael J. Hennessy Associates; Peerview; Research to Practice
Consulting or Advisory Role - Abbvie; AmerisourceBergen; Arcus Biosciences; AskGene Pharma; Astellas Pharma; AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Geneos; GlaxoSmithKline; Guardant Health; Imedex; Imugene; Jazz Pharmaceuticals; Lilly; Lynx Health; Merck; Merck Serono; Mersana; Michael J. Hennessy Associates; Paradigm; Peerview; Pfizer; Phanes Therapeutics; Research to Practice; Rgenix; Seagen; Silverback Therapeutics; Zymeworks
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cycle for Survival (Inst); Department of Defense (Inst); Fred's Team (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NCI (Inst); Rgenix (Inst); Transcenta (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb Japan; Merck
Other Relationship - Axis Medical Education; Clinical Care Options; Research to Practice
 
Akihito Kawazoe
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Zymeworks
Speakers' Bureau - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Jianming Xu
No Relationships to Disclose
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Jean-Philippe Metges
Honoraria - Bayer; Bristol-Myers Squibb; MSD
 
Lucjan S. Wyrwicz
Honoraria - BeiGene; BMS; MSD
Consulting or Advisory Role - GlaxoSmithKline; SERVIER
Speakers' Bureau - BMS
Travel, Accommodations, Expenses - SERVIER
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Yuriy Ostapenko
Research Funding - Merck Sharp & Dohme, LLC., a subsidiary of Merck & Co., Inc (MSD) (Inst)
 
Mehmet Bilici
No Relationships to Disclose
 
Maeve Aine Lowery
Consulting or Advisory Role - AstraZeneca; Roche/Genentech; SERVIER
Research Funding - Astellas Pharma; Basilea; Exelixis; MSD
 
Adriana Valderrama
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yanfen Guan
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kan Li
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Chie-Schin Shih
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; Eutilex; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks